Novo Nordisk narrows 2026 guidance as Wegovy sales go flat
Ziltivekimab's failed ZEUS cardiovascular outcomes trial may trigger a non-cash impairment charge in the third quarter, the company said.
TR
By Tom Reyes · Markets Editor
Aug 12 03:00 ETSource: TradingView
The wire
- 01Novo said second-quarter injectable Wegovy sales were flat year over year and narrowed its 2026 outlook to a 0-6% decline in adjusted sales and operating profit, from 4-12%.
- 02Pipeline setbacks compound the pressure: ZEUS missed on major adverse cardiovascular events, monlunabant was discontinued, and CagriSema failed non-inferiority to Mounjaro on blood sugar in REIMAGINE 4.
- 03Novo says expanded deals with US pharmacies and telehealth platforms have largely addressed the compounded semaglutide challenge; pricing and US demand remain the near-term uncertainties.
From the source
Read at tradingview.comNovo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?
Novo Nordisk NVO stock has declined 4% over the past month, with the company’s second-quarter 2026 results emerging as the primary factor behind the recent weakness.
